Hydrokortison orion ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 41 | Giant cell arteritis | 1 |
41. Giant cell arteritis
Clinical trials : 128 / Drugs : 139 - (DrugBank : 36) / Drug target genes : 33 - Drug target pathways : 124
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-002528-18-DK (EUCTR) | 22/02/2022 | 30/07/2021 | RESCUE - Effect of supplemental hydrocortisone during stress in prednisolone-induced adrenal insufficiency. | RESCUE - Effect of supplemental hydrocortisone during stress in prednisolone-induced adrenal insufficiency; A multicentre, randomised, double blinded, placebo-controlled clinical trial on health-related quality of life in patients with polymyalgia rheumatica/giant cell arteritis receiving ongoing low-dose prednisolone treatment. - RESCUE | Glucocorticoid-induced adrenal insufficiency MedDRA version: 20.0;Level: LLT;Classification code 10001369;Term: Adrenal insufficiency NOS;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Hydrokortison orion Product Name: hydrokortison Product Code: H02AB09 INN or Proposed INN: hydrocortisone Other descriptive name: HYDROCORTISONE | Copenhagen University Hospital Rigshospitalet | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 325 | Phase 4 | Denmark |